SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Amendment No. 5
Under the Securities Exchange Act of 1934
Flamel Technologies S.A.
--------------------------
(Name of Issuer)
Ordinary Shares
--------------------------
(Title of Class of Securities)
338488 10 9
--------------------------
(CUSIP Number)
Hilary Strain
One Embarcadero Center, Suite 4050
San Francisco, CA 94111
(415) 362-4022
--------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
October 2, 2003
--------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box
[ ].
Check the following box if a fee is being paid with this statement [ ].
(A fee is not required only if the reporting person: (1) has a previous
statement on file reporting beneficial ownership of more than five percent of
the class of securities described in Item 1; and (2) has filed no amendment
subsequent thereto reporting beneficial ownership of five percent or less of
such class. (See Rule 13d-7).
Note: Six copies of this statement, including all exhibits, should be
filed with the Commission. See Rule 13d-1(a) for other parties to whom copies
are to be sent.
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934, as amended (the "Exchange Act") or otherwise subject to the
liabilities of that section of the Exchange Act but shall be subject to all
other provisions of the Exchange Act.
(Continued on following page(s))
Page 1 of 16 Pages
CUSIP No. 0338488 10 9 13D Page 2 of 16 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos. of Above
Persons
Alta Partners
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b) X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
WC
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
California
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power -0-
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power -0-
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
-0- Exit Filing
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
0% Exit Filing
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
CUSIP No. 0338488 10 9 13D Page 3 of 16 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos. of Above
Persons
Alta BioPharma Partners, L.P.
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b) X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
WC
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
Delaware
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power -0-
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power -0-
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
-0- Exit Filing
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
0% Exit Filing
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
PN
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
CUSIP No. 0338488 10 9 13D Page 4 of 16 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos. of Above
Persons
Alta Embarcadero BioPharma, LLC
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b) X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
WC
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
California
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power -0-
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power -0-
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
-0- Exit Filing
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
0% Exit Filing
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
CUSIP No. 0338488 10 9 13D Page 5 of 16 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos. of Above
Persons
Flamel Chase Partners (Alta Bio), LLC
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b) X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
WC
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
Delaware
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power -0-
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power -0-
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
-0- Exit Filing
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
0% Exit Filing
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
CUSIP No. 0338488 10 9 13D Page 6 of 16 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos. of Above
Persons
Alta BioPharma Management, LLC
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b) X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
WC
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
Delaware
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power -0-
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power -0-
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
-0- Exit Filing
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
0% Exit Filing
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
CUSIP No. 0338488 10 9 13D Page 7 of 16 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos. of Above
Persons
Alta/Chase BioPharma Management, LLC
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b) X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
WC
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
Delaware
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power -0-
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power -0-
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
-0- Exit Filing
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
0% Exit Filing
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
CUSIP No. 0338488 10 9 13D Page 8 of 16 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos. of Above
Persons
Jean Deleage
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b) X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
AF
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
U.S.A.
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power 1
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
Footnote 1
(9) Sole Dispositive Power 1
(10) Shared Dispositive Power -0-
Footnote 1
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
1 Please see Footnote 1 Exit Filing
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
0% Exit Filing
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
IN
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
Footnote 7: Jean Deleage owns one share of Flamel Ordinary stock.
CUSIP No. 0338488 10 9 13D Page 9 of 16 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos. of Above
Persons
Garrett Gruener
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b) X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
AF
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
U.S.A.
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power -0-
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power -0-
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
-0- Exit Filing
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
0% Exit Filing
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
IN
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
CUSIP No. 0338488 10 9 13D Page 10 of 16 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos. of Above
Persons
Daniel Janney
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b) X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
AF
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
U.S.A.
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power -0-
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power -0-
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
-0- Exit Filing
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
0% Exit Filing
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
IN
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
CUSIP No. 0338488 10 9 13D Page 11 of 16 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos. of Above
Persons
Alix Marduel
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b) X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
AF
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
U.S.A.
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power -0-
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power -0-
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
-0- Exit Filing
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
0% Exit Filing
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
IN
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
CUSIP No. 0338488 10 9 13D Page 12 of 16 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos. of Above
Persons
Guy Nohra
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b) X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
AF
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
U.S.A.
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power -0-
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power -0-
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
-0- Exit Filing
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
0% Exit Filing
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
IN
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
Item 1. Security and Issuer.
This Statement on Schedule D relates to the Ordinary Shares,
$0.080 French franc par value per share (the "Shares"), of Flamel Technologies,
S.A., a French Societe Anonyme organized under the laws of The Republic of
France (the "Company"). The principal executive offices of the Company are
located at Parc Club Du Moulin a Vent, 33, avenue de Dr. Georges Levy,
Venissieux, Cedex 69693, France.
EXIT FILING --- On October 2 and 8, 2003, the funds affiliated
with Alta Partners sold all its holdings in Flamel Technologies, S.A. Alta
BioPharma Partners, L.P. sold 1,351,954 shares (exercised from warrants
previously held and subsequently converted into ADS's) of the Issuers Ordinary
Stock, Flamel Chase Partners (Alta Bio), LLC sold 772,088 shares (exercised from
warrants previously held and subsequently converted into ADS's) of the Issuer's
Ordinary Stock and Alta Embarcadero BioPharma Partners, LLC sold 50,958 shares
(exercised from warrants previously held and subsequently converted into ADS's)
of the Issuer's Ordinary Stock.
Item 2. Identity and Background.
(a) This Exit Filing is filed by (i) Alta BioPharma Partners,
L.P., a Delaware limited partnership ("Alta BioPharma") by virtue of having been
a record owner that sold its holdings of 1,351,954 shares (exercised from
warrants previously held and subsequently converted into ADS's) of the Issuer's
Ordinary Stock on October 2 and 8, 2003, (ii) Alta Embarcadero BioPharma
Partners, LLC, a California limited liability company ("Embarcadero LLC") by
virtue of having been a record owner that sold 50,958 shares (exercised from
warrants previously held and subsequently converted into ADS's) of the Issuer's
Ordinary Stock on October 2 and 8, 2003, and (iii) Flamel Chase Partners (Alta
Bio), LLC, a Delaware limited liability company ("Flamel Alta Bio") by virtue of
having been a record owner that sold its 772,088 shares (exercised from warrants
previously held and subsequently converted into ADS's) of the Issuer's Ordinary
Stock on October 2 and 8, 2003, and (iv) Alta BioPharma Management Partners,
LLC, a Delaware limited liability company ("Alta Management"), by virtue of
being the sole general partner of Alta BioPharma; (v) Alta/Chase BioPharma
Management LLC, a Delaware limited liability company (Alta/Chase Management) by
virtue of being the sole managing member of Flamel Chase Partners (Alta Bio),
LLC and (vi) Alta Partners, a California corporation ("Alta Partners"), by
virtue of being the management advisory company of these entities. Alta
BioPharma, Embarcadero LLC, Flamel Alta Bio, Alta Management, Alta/Chase
Management and Alta Partners are collectively referred to as the "Reporting
Persons." Jean Deleage, Garrett Gruener, Daniel Janney, Alix Marduel, and Guy
Nohra (the "Managing Directors") are the managing directors and members of Alta
Management, Alta/Chase Management and officers of Alta Partners. By virtue of
the relationships described above and their roles with Alta Partners, each of
the managing directors and members may be deemed to control Alta Partners,
Alta/Chase Management, Alta Management, and, therefore, may be deemed to possess
indirect beneficial ownership of the shares held by each entity. However, none
of the managing directors, acting alone, has voting or investment power with
respect to the shares directly beneficially held by the entities and, as a
result, the managing directors disclaim beneficial ownership of the shares
beneficially owned by each entity, except to the extent of their proportionate
pecuniary interests therein. Embarcadero LLC is a side company that makes all
investments pro rata to the capital of Alta BioPharma with all allocations made
to its members based on paid-in capital. Certain managing directors are members
of Embarcadero LLC and certain members of Embarcadero LLC are affiliates of Alta
Partners.
(b) The principal executive offices of Alta BioPharma,
Embarcadero LLC, Flamel Chase Alta Bio, Alta Management, Alta/Chase Management
and Alta Partners, and the business address of each Partner, are located at One
Embarcadero Center, Suite 4050, San Francisco, California 94111.
(c) Alta Partners provides investment advisory services to
venture capital firms. Alta BioPharma, Flamel Chase Alta Bio and Embarcadero
LLC's principal business is acting as venture capital investment vehicles.
Alta/Chase Management and Alta Management's principal business is acting as
managing director of Flamel Chase Alta Bio and Alta BioPharma, respectively.
Each of the Directors' principal business is acting as a managing director of
Alta Management and Alta/Chase Management and as a director of Alta Partners.
Page 13 of 16 Pages
(d) None of the Reporting Persons or, to the knowledge of the
Reporting Persons, any of the managing directors, has been convicted in a
criminal proceeding in the past five years (excluding traffic violations or
similar misdemeanors).
(e) During the past five years, none of the Reporting Persons
or, to the knowledge of the Reporting Persons, and none of the managing
directors, was a party to a civil proceeding of a judicial or administrative
body of competent jurisdiction as a result of which such person was or is
subject to a judgment, decree or final order enjoining future violations of, or
prohibiting or mandating activities subject to, federal or state securities laws
of finding any violation with respect to such laws.
(f) Alta Partners is a California corporation. Alta BioPharma
is a Delaware limited partnership. Embarcadero LLC is a California limited
liability corporation. Flamel Chase Alta Bio is a Delaware limited liability
company. Alta Management and Alta/Chase Management are Delaware limited
liability companies. Each of the Managing Directors is a citizen of the United
States.
(g) Jean Deleage resigned his position as a Director of Flamel
Technologies on August 13, 2001. Mr. Deleage owns one share of Ordinary Stock of
Flamel Technologies stock. He is a managing director of Alta Management,
Alta/Chase Management and a managing member of Embarcadero, LLC. By virtue of
his roles with Alta Partners, he may be deemed to share control of Alta
Partners, Alta/Chase Management, Alta Management, and, therefore, may be deemed
to possess indirect beneficial ownership of the Shares held by each entity.
However, he is not acting alone, he has voting or investment power with respect
to the shares directly beneficially held by the entities and, as a result, he
disclaims beneficial ownership of the shares directly beneficially owned by each
entity, except to the extent of their pecuniary interest in each entity.
Item 3. Source and Amount of Funds or Other Consideration.
N/A Exit Filing --- On October 2 and 8, 2003, the funds
affiliated with Alta Partners sold all their holdings in Flamel Technologies,
S.A. Alta BioPharma Partners, L.P. sold 1,351,954 shares (exercised from
warrants previously held and subsequently converted into ADS's) of the Issuer's
Ordinary Stock, Flamel Chase Partners (Alta Bio), LLC sold 772,088 shares
(exercised from warrants previously held and subsequently converted into ADS's)
of the Issuer's Ordinary Stock, and Alta Embarcadero BioPharma Partners, LLC
sold 50,958 shares (exercised from warrants previously held and subsequently
converted into ADS's) of the Issuer's Ordinary Stock.
Item 4. Purpose of Transaction.
Exit Filing --- See Item 3
Item 5. Interest in Securities of the Issuer.
Exit Filing
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to
Securities of the Issuer. Exit Filing
Item 7. Material to be Filed as Exhibits.
Exhibit A: Joint Filing Statement
Page 14 of 16 Pages
Signature
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Date: October 9, 2003
Alta Partners Alta BioPharma Partners, L.P.
By: /s/ Jean Deleage By: Alta BioPharma Management, LLC
-------------------------------------------- Its General Partner
Jean Deleage, President
Alta BioPharma Management, LLC By: /s/ Jean Deleage
--------------------------------------------
Jean Deleage, Managing Director
By: /s/ Jean Deleage Flamel Chase Partners (Alta Bio), LLC
--------------------------------------------
Jean Deleage, Managing Director
By: Alta/Chase BioPharma Management, LLC
Alta/Chase BioPharma Management, LLC Its Managing Member
By: /s/ Jean Deleage By: /s/ Jean Deleage
-------------------------------------------- --------------------------------------------
Jean Deleage, Member Jean Deleage, Member
Alta Embarcadero BioPharma Partners, LLC
By: /s/ Jean Deleage
--------------------------------------------
Jean Deleage, Member
/s/ Jean Deleage /s/ Guy Nohra
- ----------------------------------------------------- -----------------------------------------------------
Jean Deleage Guy Nohra
/s/ Garrett Gruener /s/ Alix Marduel
- ----------------------------------------------------- -----------------------------------------------------
Garrett Gruener Alix Marduel
/s/ Daniel Janney
- -----------------------------------------------------
Daniel Janney
Page 15 of 16 Pages
EXHIBIT A
Joint Filing Statement
We, the undersigned, hereby express our agreement that the attached
Schedule 13D is filed on behalf of each of us.
Date: October 9, 2003
Alta Partners Alta BioPharma Partners, L.P.
By: /s/ Jean Deleage By: Alta BioPharma Management, LLC
-------------------------------------------- Its General Partner
Jean Deleage, President
Alta BioPharma Management, LLC By: /s/ Jean Deleage
--------------------------------------------
Jean Deleage, Managing Director
By: /s/ Jean Deleage Flamel Chase Partners (Alta Bio), LLC
--------------------------------------------
Jean Deleage, Managing Director
By: Alta/Chase BioPharma Management, LLC
Alta/Chase BioPharma Management, LLC Its Managing Member
By: /s/ Jean Deleage By: /s/ Jean Deleage
-------------------------------------------- --------------------------------------------
Jean Deleage, Member Jean Deleage, Member
Alta Embarcadero BioPharma Partners, LLC
By: /s/ Jean Deleage
--------------------------------------------
Jean Deleage, Member
/s/ Jean Deleage /s/ Guy Nohra
- ----------------------------------------------------- -----------------------------------------------------
Jean Deleage Guy Nohra
/s/ Garrett Gruener /s/ Alix Marduel
- ----------------------------------------------------- -----------------------------------------------------
Garrett Gruener Alix Marduel
/s/ Daniel Janney
- -----------------------------------------------------
Daniel Janney
Page 16 of 16 Pages